Flexion Therapeutics Inc (OQ:FLXN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 10 Mall Rd Ste 301
BURLINGTON MA 01803-4121
Tel: 1-781-3057194
Website: flexiontherapeutics.com
IR: See website
Key People
Patrick J. Mahaffy
Independent Chairman of the Board
Michael D. Clayman
President, Chief Executive Officer, Director
David A. Arkowitz
Chief Financial Officer
Mark Levine
General Counsel and Corporate Secretary
Scott D. Kelley
Chief Medical Officer
Melissa Layman
Chief Commercial Officer
Kerry Wentworth
Chief Regulatory Officer
Christina Willwerth
Chief Strategy Officer
Business Overview
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Financial Overview
For the three months ended 31 March 2020, Flexion Therapeutics Inc revenues increased 91% to $20.1M. Net loss decreased 11% to $36.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General & admn exp decrease of 9% to $26.9M (expense), Stock-based Compensation in SGA decrease of 9% to $2.4M (expense).
Employees: 288 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $694.12M as of Jun 30, 2020
Annual revenue (TTM): $82.52M as of Jun 30, 2020
EBITDA (TTM): -$128.97M as of Jun 30, 2020
Net annual income (TTM): -$145.04M as of Jun 30, 2020
Free cash flow (TTM): -$145.04M as of Jun 30, 2020
Net Debt Last Fiscal Year: $90.73M as of Jun 30, 2020
Shares outstanding: 47,793,192 as of May 20, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.